Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Delirium: non-drug and drug management

Medicine of older adults · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Danger with an untreated cause

Severe agitation, pulling essential treatment, violence or inability to receive life-saving care may coexist with hypoxia, sepsis, pain, retention, withdrawal or intracranial disease; sedation can conceal deterioration and compromise airway or circulation.

Action: Call senior help, stabilise physiology, reduce stimulation and use one trained communicator, treat pain and reversible triggers, make the environment safe and use the lowest short medicine dose only when distress or risk remains and verbal de-escalation is ineffective or inappropriate.

Synopsis

Treat delirium through urgent cause control and skilled non-drug care, de-escalate distress while preserving communication and mobility, and restrict sedating medicine to exceptional short-term safety indications with Parkinson and Lewy-body safeguards.

  • Cause treatment and multicomponent non-drug care are first-line delirium management; no medicine cures the syndrome.
  • Use one calm communicator, introduce each action, validate fear, offer simple choices, restore glasses and hearing aids and involve familiar people when wanted.
  • Meet physical needs: oxygen when indicated, analgesia, hydration, nutrition, toilet, bowel care, temperature comfort, sleep and safe mobilisation.
  • Reduce noise, crowding, ward moves, alarms and unnecessary devices while maintaining daylight, clock, calendar and repeated orientation.
  • If the person is distressed or risks harm, attempt verbal and non-verbal de-escalation before medicine unless immediate danger makes this inappropriate.
  • NICE permits short-term haloperidol, usually one week or less, only when de-escalation fails or is inappropriate and distress or risk remains.
  • Before haloperidol, check Parkinson or DLB, cardiac history, QT-prolonging drugs, ECG and electrolytes and use the lowest dose for the shortest time.
  • A frail older-adult emergency regimen may begin haloperidol 0.5 mg orally once with reassessment; follow the local typed protocol and avoid automatic repeat dosing.
  • Avoid haloperidol in Parkinson disease and DLB. Seek specialist advice; medication alternatives are off-label and still carry sedation, stroke and mortality risk.
  • Benzodiazepines usually worsen ordinary delirium; reserve them for alcohol or benzodiazepine withdrawal, catatonia or a specialist indication.

Key red flags

Never sedate agitation before checking oxygenation, glucose, pain, retention, constipation, withdrawal, medication toxicity and new neurological signs.

Parkinson disease or dementia with Lewy bodies creates marked neuroleptic sensitivity; haloperidol can cause rigidity, aspiration, reduced consciousness and death.

QT prolongation, bradycardia, electrolyte disturbance, cardiac disease or interacting medicines increases torsade risk and requires ECG-informed avoidance or correction.

Fever, severe rigidity, reduced consciousness and autonomic instability after an antipsychotic suggests neuroleptic malignant syndrome and requires immediate cessation and emergency care.

Alcohol or benzodiazepine withdrawal needs a specific benzodiazepine regimen and thiamine pathway rather than ordinary delirium sedation.

Restraint, repeated security presence or forced care can amplify fear and injury; any restriction requires immediate necessity, proportionality and frequent review.

Immediate safety crisis

Investigation priorities

01
Repeat physiological assessmentFirst step

Detect a new or untreated medical driver.

Management branches

First-line non-drug managementTreat causes and reduce threat

Delirium is recognised with distress, disorientation or unsafe behaviour.

  1. Correct physiological and medical drivers and provide pain, hydration, nutrition, bowel, bladder and sensory care.
  2. Use one calm communicator, familiar support, orientation, low-stimulation space, sleep protection and safe mobilisation.
  3. Review response and capacity frequently and remove unnecessary devices and restrictions.

Key medicines

HaloperidolFor a severely distressed or dangerous frail older adult, a typed local protocol commonly starts 0.5 mg orally once, reassesses after one to two hours and limits total exposure; NICE advises treatment usually for one week or less.Avoid Parkinson disease and DLB, prolonged QT and major cardiac risk; obtain ECG and correct electrolytes, monitor rigidity, akathisia, dysphagia and sedation, and stop promptly.
LorazepamFor ordinary delirium avoid routine use; when a specialist identifies catatonia or a specific withdrawal indication, a cautious older-adult test dose may be 0.5 mg orally or parenterally with monitored reassessment.Can cause paradoxical agitation, falls, aspiration and respiratory depression; reduce in frailty and never combine casually with opioids or repeat without response assessment.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG103 delirium recommendationsCause treatment, de-escalation and narrow short-term haloperidol indication.
  • MHRA haloperidol reminder in older deliriumECG, dosing, extrapyramidal, DLB and Parkinson safety.
  • NICE NG97 dementia recommendationsAntipsychotic risk, DLB sensitivity and non-drug distress management.
  • British Geriatrics Society CGA HubFunction, communication, environment, medicines and carers in older-adult care.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

The person is about to cause serious harm or prevent essential life-saving treatment despite skilled de-escalation.

Neuroleptic sensitivity

After dopamine blockade, marked rigidity, somnolence, dysphagia or autonomic deterioration suggests DLB or Parkinson vulnerability.